Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables: 2010-2024

Historic Receivables for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $47.1 million.

  • Vanda Pharmaceuticals' Receivables rose 18.22% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.2 million, marking a year-over-year increase of 20.42%. This contributed to the annual value of $47.1 million for FY2024, which is 37.90% up from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' Receivables is $47.1 million, which was up 37.90% from $34.2 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Receivables registered a high of $47.1 million during FY2024, and its lowest value of $30.0 million during FY2020.
  • In the last 3 years, Vanda Pharmaceuticals' Receivables had a median value of $34.2 million in 2023 and averaged $38.3 million.
  • Data for Vanda Pharmaceuticals' Receivables shows a peak YoY surged of 37.90% (in 2024) over the last 5 years.
  • Vanda Pharmaceuticals' Receivables (Yearly) stood at $30.0 million in 2020, then climbed by 8.09% to $32.5 million in 2021, then grew by 3.22% to $33.5 million in 2022, then climbed by 1.92% to $34.2 million in 2023, then spiked by 37.90% to $47.1 million in 2024.